Uveitis as the first symptom in spondyloarthritis and its association with the evolution of the disease. Results from the REGISPONSER registry - 29/04/21
, María Lourdes Ladehesa-Pineda a, María Ángeles Puche-Larrubia a, Rafaela Ortega-Castro a, b, Pilar Font-Ugalde a, b, Verónica Pérez-Guijo a, b, Alejandro Escudero-Contreras a, b, Gonzalo Diaz-Villalón b, Clementina López-Medina a, c, 1, Eduardo Collantes-Estévez a, b, 1Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
| pages | 6 |
| Iconographies | 1 |
| Vidéos | 0 |
| Autres | 0 |
Highlights |
• | The prevalence of acute anterior uveitis in the REGISPONSER population was 16.2%. |
• | Patients with acute anterior uveitis as first symptom showed a better function and less structural damage than patients with uveitis after the rheumatic symptoms onset. |
• | The moment of appearance of acute anterior uveitis had no impact on the treatment received. |
Abstract |
Objectives |
To describe the time of onset of acute anterior uveitis (AAU) relative to the appearance of rheumatic symptoms and to determine its association with the evolution of the spondyloarthritis (SpA) in terms of activity, structural damage, functional ability and treatment.
Methods |
This was a cross-sectional study with data extracted from the REGISPONSER (SpA Registry of the Spanish Rheumatology Society). Thirty-one centres participated, and patients with SpA according to the ESSG criteria were included from 2004 to 2007. Patients were classified according to the time of uveitis appearance with regard to rheumatic symptom onset (before, concomitant with, or after rheumatic symptom onset). We compared the clinical characteristics, disease activity, radiographic damage and functional ability between “AAU before or concomitant with rheumatic symptoms” and “AAU after rheumatic symptoms onset”. Finally, we compared whether the time of appearance of AAU had an impact on the use of conventional and biological disease-modifying antirheumatic drugs (csDMARDs and bDMARDs, respectively).
Results |
A total of 2367 patients were included in REGISPONSER, with an AAU prevalence of 16.2% (379 patients). Patients with AAU before/concomitant with rheumatic symptom onset (n=59) exhibited better functional ability (BASFI, OR 0.85 [0.73-0.99]) and less structural damage (spinal BASRI, OR 0.88 [0.79-0.99]). Additionally, this group of patients was older at SpA symptom onset (OR 1.05 [1.02-1.09]) and had a shorter diagnosis delay (OR 0.90 [0.84-0.96]) compared patients with AAU after rheumatic symptom onset (n=229). No statistically significant differences in the use of DMARDs were noted (27.9% vs 23.2% for csDMARD use and 15.3% vs 20.3% for bDMARD use in patients with AAU before or concomitant with rheumatic symptom onset vs after rheumatic symptom onset, respectively).
Conclusion |
Patients presenting with a first episode of AAU before/concomitant with the onset of rheumatic symptoms had less severe disease (better functional ability and less structural damage) and a shorter diagnosis delay; however, the time of AAU onset did not impact the treatments received.
Le texte complet de cet article est disponible en PDF.Keywords : Spondyloarthritis, Uveitis, Prognosis
Plan
Vol 88 - N° 3
Article 105136- mai 2021 Retour au numéro
Article précédent
- HLA association with the susceptibility to anti-synthetase syndrome
- Sara Remuzgo-Martínez, Belén Atienza-Mateo, J. Gonzalo Ocejo-Vinyals, Verónica Pulito-Cueto, Diana Prieto-Peña, Fernanda Genre, Ana Marquez, Javier Llorca, Víctor M. Mora Cuesta, David Iturbe Fernández, Laura Riesco, Norberto Ortego-Centeno, Nair Pérez Gómez, Antonio Mera, Julia Martínez-Barrio, Francisco Javier López-Longo, Leticia Lera-Gómez, Clara Moriano, Elvira Díez, Eva Tomero, Jaime Calvo-Alén, Fredeswinda Romero-Bueno, Olga Sanchez-Pernaute, Laura Nuño, Gema Bonilla, Ignacio Grafia, Sergio Prieto-González, Javier Narvaez, Ernesto Trallero-Araguas, Albert Selva-O’Callaghan, Oreste Gualillo, Javier Martín, Lorenzo Cavagna, Santos Castañeda, José M. Cifrian, Elisabetta A. Renzoni, Raquel López-Mejías, Miguel A. González-Gay
- Tocilizumab controls bone turnover in early polymyalgia rheumatica
- Guillermo Carvajal Alegria, Florent Garrigues, Eleonore Bettacchioli, Damien Loeuille, Alain Saraux, Divi Cornec, Valérie Devauchelle-Pensec, Yves Renaudineau
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’achat d’article à l’unité est indisponible à l’heure actuelle.
Déjà abonné à cette revue ?